---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Diagnosis"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Diagnosis. Topics: Diagnostic steps: medical history, physical examination, photographs, and basic tests; Aims of the diagnostic workup in CSU: 2026 international guideline; Routine laboratory tests: differential blood count, CRP or ESR, total IgE, and IgG anti-TPO; Differential diagnosis: urticarial vasculitis, autoinflammatory disorders, and bradykinin-mediated angioedema; 15 further topics. 19 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/diagnosis"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Diagnostic steps: medical history, physical examination, photographs, and basic tests

> “A detailed medical history is essential in the diagnosis of urticaria”
> “is the first step in the diagnostic workup of all urticaria patients. This clinical anamnesis should include concomitant and comorbid diseases. The second step is the physical examination of the patient.”
> “Since wheals and angioedema are transient and may not be present at the time of physical examination, it is important to review prior documentation, including patient‐provided photographs of wheals and/or angioedema”
> “In CU, the third step involves a basic diagnostic workup which includes a limited set of recommended diagnostic tests”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-2"></a>

### Aims of the diagnostic workup in CSU: 2026 international guideline

> “In CSU, the diagnostic workup has seven major aims: (i) to confirm the diagnosis and exclude differential diagnoses, especially for angioedema‐only patients; (ii) to look for the underlying causes; (iii) to identify relevant conditions that modify disease activity; (iv) to check for comorbidities; (v) to identify the consequences of CSU; (vi) to assess predictors of the course of disease and response to treatment; and (vii) to monitor disease activity, impact, and control”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-3"></a>

### Routine laboratory tests: differential blood count, CRP or ESR, total IgE, and IgG anti-TPO

> “We recommend limited investigations. Basic tests include differential blood count, CRP and/or ESR, and in specialized care total IgE and IgG anti‐TPO, and more biomarkers as appropriate. We recommend performing further diagnostic measures based on the patient history and examination, especially in patients with long standing and/or uncontrolled disease.”
> “The basic tests include a differential blood count, CRP and/or ESR (to rule out severe systemic disease, as an indicator for parasitic disease, eosinophilic count, autoimmune disease such as systemic lupus), in all patients. In patients under specialist care, additional tests, such as total IgE and IgG‐anti‐TPO may be performed, as they indicate the likelihood of response to omalizumab”
> “However, although a clinical association between these laboratory markers and urticaria endotypes has been demonstrated, their clinical usefulness remains limited because there are no studies evaluating their diagnostic accuracy. Currently, cutoff points can be suggested but cannot be recommended for definitive endotype classification”
> “Intensive and costly general screening programs for causes of urticaria are not advised.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-4"></a>

### Differential diagnosis: urticarial vasculitis, autoinflammatory disorders, and bradykinin-mediated angioedema

> “In patients who exclusively develop wheals (but not angioedema), urticarial vasculitis”
> “such as Schnitzler syndrome or cryopyrin‐associated periodic syndromes (CAPS), need to be ruled out.”
> “On the other hand, in patients who suffer exclusively from recurrent angioedema (but not from wheals), differential diagnosis should include bradykinin‐mediated angioedema, including those induced by angiotensin‐converting enzyme (ACE)‐inhibitor or gliptins, or hereditary angioedema (HAE)”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-5"></a>

### Limited laboratory testing: 2014 AAAAI practice parameter and international guideline tests

> “However, empiric elimination diets (not guided by history and testing) and extensive laboratory evaluation are not recommended in the diagnosis of urticaria.”
> “The limited testing that has been suggested by the international guidelines and the AAAAI Practice Parameter Update 2014 (A-PP) includes a CBC with diff, ESR or CRP, liver enzymes and TSH.”

Source: [Bernstein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12180992/)

<a id="topic-2.2.1.5-6"></a>

### Diagnostic delay: CURE registry, 4,332 adults with chronic urticaria

> “We retrospectively analysed data from CU adult patients from the international, multicenter Chronic Urticaria Registry (CURE).”
> “Of 4332 CU patients, 61% had standalone chronic spontaneous urticaria (sCSU), 18% had ≥ 1 form of chronic inducible urticaria (CIndU), and 21% had a combination of both (CSU + CIndU).”
> “Diagnosis of CU was delayed in 24% of patients by at least 1 year.”
> “CIndU patients showed a longer DD compared to those with sCSU or CSU + CIndU (median, [IQR]: 4, [0-22] vs. 1, [0-6] vs. 2, [0-9] months, p < 0.001).”
> “In CSU patients, a DD of ≥ 6 months was associated with lower CSU activity (median weekly Urticaria Activity Score of 14 vs. 21, p = 0.02) compared to that of DD < 6 months.”

Source: [Muñoz et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41532284/)

<a id="topic-2.2.1.5-7"></a>

### Time from symptom onset to diagnosis: 673 adults with inadequately controlled CSU

> “This international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for ≥12 months despite treatment.”
> “The mean (SD) duration of disease from symptom onset to diagnosis was 24.0 (63.36) months (median 4.7 months) and from diagnosis to the time of study enrollment was 57.7 (77.79) months (median 27.7 months).”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

<a id="topic-2.2.1.5-8"></a>

### Diagnosing clinicians: physician-diagnosed CSU in a 2019 United States survey

> “Allergists (39.8%), followed by primary care physicians (36.3%) and dermatologists (16.4%), were the most frequent diagnosticians responsible for CSU diagnosis.”
> “UCT scores show that 77.0% of respondents had a score ≤11, indicating poorly controlled CSU.”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.5-9"></a>

### Disease activity instruments: UAS7 and AAS recommendations and score ranges

> “We recommend the use of the urticaria activity score, UAS7, and/or of the angioedema activity score, AAS, for assessing disease activity in patients with chronic spontaneous urticaria.”
> “The UAS7, calculated as the sum of daily scores over 7 consecutive days, should be routinely used to monitor disease activity and treatment response in patients with CSU.”
> “For CSU patients who develop angioedema, with or without wheals, the Angioedema Activity Score (AAS) should be used to assess disease activity”
> “CSU patients who experience wheals and angioedema should use the UAS7 and the AAS in combination.”
> “For the UAS7 the sum of the score (0–3 for wheals +0–3 for pruritis) for each day is summarized over 1 week (7 days) for a maximum of 42.”
> “For the AAS, scores are summed up to an AAS day sum score (0–15), 7 AAS day sum scores to an AAS week sum score (AAS7, 0–105), and 4 ASS week sum scores may be summed up to an AAS 4‐week sum score (AAS28, 0–420).”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-10"></a>

### Daily UAS scores for wheals and pruritus

| UAS score | Wheals | Pruritus |
| --- | --- | --- |
| 0 | “None” | “None” |
| 1 | “Mild (< 20 wheals/24 h)” | “Mild (present but not annoying or troublesome)” |
| 2 | “Moderate (20–50 wheals/24 h)” | “Moderate (troublesome but does not interfere with normal daily activity or sleep)” |
| 3 | “Intense (> 50 wheals/24 h or large confluent areas of wheals)” | “Intense (severe pruritus, which is sufficiently troublesome to interfere with normal daily activity or sleep)” |

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-11"></a>

### UAS7 disease activity bands: pooled omalizumab trials, twice-daily UAS7

> “A weekly Urticaria Activity Score – here, the average of twice‐daily patient assessment of itch and hives scores summed over 1 week (UAS7TD) – measures severity from 0 to 42.”
> “Data from three randomized clinical trials of omalizumab in CSU were pooled.”
> “Scores were categorized into five disease states: urticaria‐free (UAS7TD = 0), well‐controlled urticaria (UAS7TD = 1–6), mild‐activity urticaria (UAS7TD = 7–15), moderate‐activity urticaria (UAS7TD = 16–27) and severe activity urticaria (UAS7TD = 28–42)”

Source: [Stull et al. (2017)](https://doi.org/10.1111/bjd.15454)

<a id="topic-2.2.1.5-12"></a>

### UAS7 minimal important difference: omalizumab trial participants

> “Seventy-three subjects with CIU completed the UAS with enhanced instructions, other measures of disease activity including the size of the largest hive, and collateral measures during a multicenter, randomized, double-blind, placebo-controlled study of omalizumab for the treatment of CIU.”
> “The MID ranged from 9.5 to 10.5 for the UAS7, 5.0 to 5.5 for number of hives (weekly average), and 4.5 to 5.0 for pruritus and size of largest hive (weekly average).”

Source: [Mathias et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22192960/)

> “One hundred thirty adult patients with chronic spontaneous urticaria completed both UAS7 versions, the Patients Global Assessment (PatGA) of disease activity, the Urticaria Control Test (UCT), the Chronic Urticaria Quality of Life Questionnaire, and the Dermatology Life Quality Index before and after the initiation of omalizumab therapy.”
> “The MID was 11 for the UAS7 (SDC = 12) and 12 for the UAS7TD (SDC = 11).”

Source: [Hawro et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29128337/)

<a id="topic-2.2.1.5-13"></a>

### Disease control instruments: UCT and AECT recommendations and cutoffs

> “We recommend the use of the urticaria control test, UCT, and/or the angioedema control test, AECT, for assessing disease control in patients with CSU.”
> “The UCT cutoff value for well‐controlled disease is 12 out of 16 possible points.”
> “Two versions of the AECT exist, one with a 4‐week recall period and one with a 3‐month recall period.”
> “The AECT consists, like the UCT, of only four questions. Its cut off for well controlled disease is 10 points.”
> “In patients who are in the range of UCT 12–15, therefore a step up might also be required.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-14"></a>

### Treatment goal of complete control: UAS of 0 and UCT of 16

> “The goal of treatment is to treat the disease until it is gone, as efficiently and as safely as possible, aiming at a continuous complete control (consistently UAS = 0/UCT = 16) and a normalization of quality of life”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.5-15"></a>

### UCT development, score range, and cutoff of 12 for controlled disease

> “A 4-item UCT with a recall period of 4 weeks was developed based on 25 potential UCT items tested in 508 patients with chronic urticaria.”
> “Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.”
> “Taken together, we recommend a UCT cutoff value of 12 for controlled disease (ie, all patients exhibiting UCT values of ≤11 are considered to have poorly controlled disease).”

Source: [Weller et al. (2014)](https://doi.org/10.1016/j.jaci.2013.12.1076)

<a id="topic-2.2.1.5-16"></a>

### UCT minimal important difference: 65 adults with difficult-to-treat CSU

> “We investigated 65 consecutive adult patients with difficult-to-treat CSU (ie, patients with insufficient responses to regular and increased doses of second-generation H1-antihistamines).”
> “Accordingly, we regard a MID of 3 points as most appropriate for UCT score changes.”

Source: [Ohanyan et al. (2017)](https://doi.org/10.1016/j.jaci.2017.04.050)

<a id="topic-2.2.1.5-17"></a>

### AECT development and cutoff of 10 for well-controlled recurrent angioedema

> “A 4-item AECT with recall periods of 4 weeks and 3 months was developed based on 106 potential items tested in 97 patients with mast cell mediator-induced (n = 49) or bradykinin-mediated recurrent AE (n = 48).”

Source: [Weller et al. (2020a)](https://pubmed.ncbi.nlm.nih.gov/31815297/)

> “A stratification of AECT scores into different levels of disease control together with a receiver-operating characteristic curve analysis suggested a cutoff value of 10 or more points to identify patients with well-controlled RA versus less than 10 points to identify patients with poorly controlled disease for both AECT versions.”

Source: [Weller et al. (2020b)](https://pubmed.ncbi.nlm.nih.gov/32173507/)

<a id="topic-2.2.1.5-18"></a>

### AECT minimal clinically important difference

> “Patients with recurrent angioedema due to chronic spontaneous urticaria, hereditary angioedema, or acquired C1‐inhibitor deficiency were repeatedly asked to complete the AECT”
> “The MCID was found to be three points for improvement of angioedema control.”

Source: [Fijen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10472988/)

<a id="topic-2.2.1.5-19"></a>

### AAS development and validation in recurrent angioedema

> “Recurrent angioedema (RecA) is a frequent clinical problem characterized by suddenly occurring cutaneous and/or mucosal swellings.”
> “In total, data from 110 and 80 RecA patients were used during the AAS item evaluation and validation phase, respectively.”
> “The resulting AAS consisted of five items and was found to have a one-dimensional structure and excellent internal consistency.”

Source: [Weller et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23919330/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf); [Bernstein et al. (2014)](https://doi.org/10.1016/j.jaci.2014.02.036)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
